GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Total Current Liabilities

VGI Health Technology (XNEC:VTL) Total Current Liabilities : A$0.00 Mil (As of . 20)


View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. VGI Health Technology's total current liabilities for the quarter that ended in . 20 was A$0.00

VGI Health Technology Total Current Liabilities Historical Data

The historical data trend for VGI Health Technology's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Total Current Liabilities Chart

VGI Health Technology Annual Data
Trend
Total Current Liabilities

VGI Health Technology Semi-Annual Data
Total Current Liabilities

VGI Health Technology Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

VGI Health Technology's Total Current Liabilities for the fiscal year that ended in . 20 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=+
+Other Current Liabilities+Current Deferred Liabilities
=+
=0.00

VGI Health Technology's Total Current Liabilities for the quarter that ended in . 20 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=+
+Other Current Liabilities+Current Deferred Liabilities
=+
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

VGI Health Technology Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

VGI Health Technology (XNEC:VTL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Total Current Liabilities
Comparable Companies
Traded in Other Exchanges
N/A
Address
19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003
Website
https://www.vgiht.com
VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines